- Home
- CRVO vs CLSD Comparison
CRVO vs CLSD Comparison
Compare CRVO & CLSD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- CLSD
- Stock Information
- Founded
- CRVO 2001
- CLSD 2011
- Country
- CRVO United States
- CLSD United States
- Employees
- CRVO N/A
- CLSD N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- CLSD Biotechnology: Pharmaceutical Preparations
- Sector
- CRVO Health Care
- CLSD Health Care
- Exchange
- CRVO Nasdaq
- CLSD Nasdaq
- Market Cap
- CRVO 98.3M
- CLSD 81.2M
- IPO Year
- CRVO N/A
- CLSD 2016
- Fundamental
- Price
- CRVO $2.28
- CLSD $0.95
- Analyst Decision
- CRVO Buy
- CLSD Strong Buy
- Analyst Count
- CRVO 8
- CLSD 6
- Target Price
- CRVO $33.00
- CLSD $5.33
- AVG Volume (30 Days)
- CRVO 98.9K
- CLSD 214.9K
- Earning Date
- CRVO 03-31-2025
- CLSD 03-11-2025
- Dividend Yield
- CRVO N/A
- CLSD N/A
- EPS Growth
- CRVO N/A
- CLSD N/A
- EPS
- CRVO N/A
- CLSD N/A
- Revenue
- CRVO $10,066,550.00
- CLSD $7,703,000.00
- Revenue This Year
- CRVO $34.17
- CLSD N/A
- Revenue Next Year
- CRVO N/A
- CLSD $91.87
- P/E Ratio
- CRVO N/A
- CLSD N/A
- Revenue Growth
- CRVO 116.29
- CLSD 248.39
- 52 Week Low
- CRVO $1.80
- CLSD $0.80
- 52 Week High
- CRVO $26.38
- CLSD $2.12
- Technical
- Relative Strength Index (RSI)
- CRVO 41.42
- CLSD 43.06
- Support Level
- CRVO $2.14
- CLSD $1.00
- Resistance Level
- CRVO $2.37
- CLSD $1.09
- Average True Range (ATR)
- CRVO 0.14
- CLSD 0.07
- MACD
- CRVO 0.09
- CLSD -0.01
- Stochastic Oscillator
- CRVO 56.41
- CLSD 16.30
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About CLSD Clearside Biomedical Inc.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye through the suprachoroidal space, or SCS. The company's novel SCS injection platform, utilizing proprietary SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases.